UKIPO seeks no-deal Brexit SPC comments

The UK Intellectual Property Office (IPO) has today, July 5, opened a consultation into supplementary protection certificate (SPC) law in the event of a ‘no deal’ Brexit.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?

20 May 2020 Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.

Big Pharma

UKIPO dismisses Swiss IP office’s bid to stop Indian pharma TM

19 November 2019 The Swiss Federal Institute of Intellectual Property has failed to stop an Indian pharmaceutical and medicine wholesaler from registering the trademark ‘Swisslife Forever’ at the UK Intellectual Property Office.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

UKIPO seeks no-deal Brexit SPC comments

More on this story

Editor's picks

Editor's picks

More features